Founded in 1956, Zhejiang Hisun Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise featuring whole chain, multi-regional integration of research, production and marketing as well as development of drug substances and preparations. In 2000, an A-share was issued in order to enter the stock market as a state-owned listed company. As of 2021, Hisun Pharmaceutical is now one of the largest producers of antibiotics and anti-tumor drugs in China and has been listed in the Top 500 Chinese manufacturing enterprises and the Top 100 Chinese pharmaceutical enterprises multiple times. In 2020 Hisun Pharmaceuticals received special recognition from the Joint Prevention and Control Team from the State Council of the People’s Republic of China for their extraordinary efforts in the fight against the epidemic, and Hisun Pharmaceutical was awarded with the “Anti COVID-19 Advanced Collective in Ministry of Industry and Information Technology". Hisun Pharmaceutical started as a chemical enterprise and entered the pharmaceutical field in the early 1970s. It has been developing its main business model for more than 60 years with total assets of 20 billion yuan and sales exceeding 10 billion yuan（RMB）. The company focuses on the research, development (R&D), production and sales of innovative drugs, biological drugs, generic drugs, and high-end active pharmaceutical ingredient (API), with a portfolio of medicines covering more than ten therapeutic areas including those of anti-tumor, anti-infection, cardiovascular, endocrine, immunosuppression, antidepressant, and orthopedics treatment. Part of an early batch as highly innovative enterprises in China, Hisun Pharmaceutical is headquartered in Taizhou, where its Central Research Institute is sided by a state-level technology center, a Post-Doctoral Research Center with independent postdoctoral recruitment qualification, and a provincial academy fellow workstation. Hisun Pharmaceutical remains committed to research with two-pronged approach: independent R&D and cooperative R&D. This has allowed Hisun Pharmaceutical to accelerate the development and production of new products. In recent years, we have undertaken a total of 47 national key projects on new drug R&D, won 2 second class prizes of the state technological invention award and 9 scientific and technological progress awards on provincial or ministerial level. We applied for more than 1,000 patents and more than 300 patents have been granted. We have won 5 Chinese patent excellence awards and 1 Zhejiang patent excellence award. In recent years, with the strategic goal of "focus, reduction and optimization", we have actively expanded our businesses from upstream to downstream API and drug formulations. At the same time, we, as pioneers, entered big health industry business development and expanded into the domestic market for special medicine and health foods. In terms of market share, we are in the top tier of companies for anti-infective drugs and anti-tumor drugs, with 20 products and 100 million yuan in sales for each product. We are internationally minded and a total of 80% of the company's API income comes from overseas markets, while our APIs are now exported to more than 70 countries and regions around the world. The drug formulation in the domestic sale network covers the whole of China and our medicines have been prescribed by near 10,000 hospitals. Following our mission statement of "Perseverance in drug innovation, achieving the dream of health and longevity", Hisun Pharmaceutical delivers world-class quality, embodied by Hisun's new look, dedicates itself to new medication, and promotes Hisun to become a comprehensive pharmaceutical enterprise with sustained and healthy development, thus ultimately making crucial contributions to human life and health.